PE20060305A1 - Compuestos de morfolina como inhibidores de la recaptacion de monoaminas - Google Patents
Compuestos de morfolina como inhibidores de la recaptacion de monoaminasInfo
- Publication number
- PE20060305A1 PE20060305A1 PE2005000484A PE2005000484A PE20060305A1 PE 20060305 A1 PE20060305 A1 PE 20060305A1 PE 2005000484 A PE2005000484 A PE 2005000484A PE 2005000484 A PE2005000484 A PE 2005000484A PE 20060305 A1 PE20060305 A1 PE 20060305A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- compounds
- alcoxy
- alkyl
- recaptation
- Prior art date
Links
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical class C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 5
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000001640 Fibromyalgia Diseases 0.000 abstract 1
- 208000011688 Generalised anxiety disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 abstract 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 abstract 1
- 208000029364 generalized anxiety disease Diseases 0.000 abstract 1
- 229960002748 norepinephrine Drugs 0.000 abstract 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Immunology (AREA)
- Pregnancy & Childbirth (AREA)
Abstract
SE REFIERE A COMPUESTOS DE MORFOLINA DE FORMULA (I), EN DONDE R1 ES H, ALQUILO(C1-C6), R2 ES FENILO O HETEROCICLO AROMATICO DE 5 O 6 MIEMBROS CON HETEROATOMOS DE N O S, OPCIONALMENTE SUSTITUIDO POR ALQUILO(C1-C6), ALCOXI(C1-C6), HALO, ENTRE OTROS; R3 ES ALQUILO(C1-C6), ALCOXI(C1-C6), OH, HALO, CF3, OCF3, OCHF2, CN, O ALCOXI(C1-C4)-ALQUILO(C1-C6), ENTRE OTROS, n ES DE 0 A 4, Y CUANDO n ES 2, LOS DOS GRUPOS R3 JUNTO AL FENILO PUEDEN FORMAR UN BICICLO BENZOCONDENSADO. SON COMPUESTOS PREFERIDOS: 2-[(4-CLORO-2-METOXIFENOXI)(FENIL)METIL]MORFOLINA, 5-CLORO-2-[MORFOLIN-2-IL(FENIL)METOXI]BENZONITRILO, 7-{[MORFOLIN-2-IL(FENIL)METIL]OXI}QUINOLINA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCESO DE ELABORACION Y UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS INHIBEN LA RECAPTACION DE MONOAMINAS (SEROTONINA, NORADRENALINA), POR LO QUE SON UTILES EN EL TRATAMIENTO DE ADHD, INCONTINENCIA URINARIA POR ESTRES, DEPRESION, TRANSTORNO DE ANSIEDAD GENERALIZADA, FIBROMIALGIA Y DOLOR
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0409744.0A GB0409744D0 (en) | 2004-04-30 | 2004-04-30 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060305A1 true PE20060305A1 (es) | 2006-04-22 |
Family
ID=32482498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000484A PE20060305A1 (es) | 2004-04-30 | 2005-04-28 | Compuestos de morfolina como inhibidores de la recaptacion de monoaminas |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US20050250775A1 (es) |
| EP (1) | EP1744754A1 (es) |
| JP (2) | JP4181622B2 (es) |
| KR (4) | KR20090006888A (es) |
| CN (1) | CN1950089A (es) |
| AP (1) | AP2006003767A0 (es) |
| AR (1) | AR048934A1 (es) |
| AU (1) | AU2005237301A1 (es) |
| BR (1) | BRPI0510515A (es) |
| CA (1) | CA2564990C (es) |
| CR (1) | CR8717A (es) |
| DO (1) | DOP2005000064A (es) |
| EA (1) | EA200601802A1 (es) |
| EC (1) | ECSP066958A (es) |
| GB (1) | GB0409744D0 (es) |
| GE (1) | GEP20084549B (es) |
| GT (1) | GT200500098A (es) |
| IL (1) | IL178313A0 (es) |
| MA (1) | MA28554B1 (es) |
| MX (1) | MXPA06012640A (es) |
| NI (1) | NI200600257A (es) |
| NL (1) | NL1028927C2 (es) |
| NO (1) | NO20064282L (es) |
| NZ (1) | NZ550054A (es) |
| PA (1) | PA8631601A1 (es) |
| PE (1) | PE20060305A1 (es) |
| SV (1) | SV2005002099A (es) |
| TN (1) | TNSN06347A1 (es) |
| TW (2) | TW200914431A (es) |
| UA (1) | UA86970C2 (es) |
| UY (1) | UY28873A1 (es) |
| WO (1) | WO2005105100A1 (es) |
| ZA (1) | ZA200608661B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7704527B2 (en) * | 2002-10-25 | 2010-04-27 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
| WO2005105763A1 (en) | 2004-04-30 | 2005-11-10 | Warner-Lambert Company Llc | Substituted morpholine compounds for the treatment of central nervous system disorders |
| GB0409744D0 (en) * | 2004-04-30 | 2004-06-09 | Pfizer Ltd | Novel compounds |
| US8389510B2 (en) * | 2005-11-18 | 2013-03-05 | Astrazeneca Ab | Crystalline forms |
| EP1951694A4 (en) * | 2005-11-18 | 2010-09-22 | Astrazeneca Ab | FORMS OF SALTS |
| CN101360503A (zh) * | 2005-11-18 | 2009-02-04 | 阿斯利康公司 | 液体制剂 |
| CN101360502B (zh) * | 2005-11-18 | 2012-03-14 | 阿斯利康公司 | 结晶形式 |
| EP1951693A4 (en) * | 2005-11-18 | 2012-05-30 | Astrazeneca Ab | SOLID FORMULATIONS |
| CA2641304A1 (en) * | 2006-02-01 | 2007-08-09 | Merck & Co., Inc. | Potassium channel inhibitors |
| EP1892530A1 (en) * | 2006-08-25 | 2008-02-27 | Boehringer Ingelheim Pharma GmbH & Co. KG | Method for determining transport activity of a transport protein |
| KR101103118B1 (ko) * | 2007-11-02 | 2012-01-04 | 동아제약주식회사 | 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물 |
| EP2318362B1 (en) * | 2008-07-24 | 2013-09-25 | Theravance, Inc. | 3-(phenoxyphenylmethyl)pyrrolidine compounds |
| US8637577B2 (en) | 2009-01-22 | 2014-01-28 | Absorption Pharmaceuticals, LLC | Desensitizing drug product |
| JP2012524098A (ja) * | 2009-04-15 | 2012-10-11 | セラヴァンス， インコーポレーテッド | ３−（フェノキシピロリジン−３−イル−メチル）ヘテロアリール、３−（フェニルピロリジン−３−イルメトキシ）ヘテロアリールおよび３−（ヘテロアリールピロリジン−３−イルメトキシ）ヘテロアリール化合物 |
| NZ597433A (en) * | 2009-07-13 | 2013-12-20 | Theravance Inc | 3-phenoxymethylpyrrolidine compounds |
| EP2456436B1 (en) | 2009-07-21 | 2014-06-25 | Theravance, Inc. | 3-phenoxymethylpyrrolidine compounds |
| AR077969A1 (es) | 2009-08-31 | 2011-10-05 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina comomoduladores de s1p |
| TW201206893A (en) * | 2010-07-09 | 2012-02-16 | Abbott Healthcare Products Bv | Bisaryl (thio) morpholine derivatives as S1P modulators |
| TW201643169A (zh) | 2010-07-09 | 2016-12-16 | 艾伯維股份有限公司 | 作為s1p調節劑的螺-哌啶衍生物 |
| TWI522361B (zh) | 2010-07-09 | 2016-02-21 | 艾伯維公司 | 作為s1p調節劑的稠合雜環衍生物 |
| CA2811641A1 (en) | 2010-10-11 | 2012-04-19 | Theravance, Inc. | Serotonin reuptake inhibitors |
| US8501964B2 (en) | 2010-12-03 | 2013-08-06 | Theravance, Inc. | Serotonin reuptake inhibitors |
| JP2012207995A (ja) * | 2011-03-29 | 2012-10-25 | Univ Of Fukui | 脳内ノルエピネフリン・トランスポータを標的とする放射性臭素標識ｐｅｔ分子イメージングプローブ |
| EP2745876A1 (en) * | 2012-12-21 | 2014-06-25 | Prous Institute for Biomedical Research, S.A. | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives |
| JP2017101020A (ja) * | 2015-11-25 | 2017-06-08 | 宇部興産株式会社 | 高純度フェノール化合物の製造方法 |
| EP3689866A4 (en) | 2017-09-26 | 2021-07-07 | Nippon Soda Co., Ltd. | QUINOLINE COMPOUND AND BACTERICIDAL AGENT FOR AGRICULTURE AND HORTICULTURE |
| KR20220123634A (ko) | 2019-10-31 | 2022-09-08 | 이스케이프 바이오, 인크. | S1p-수용체 조절제의 고체 형태 |
| CN113185384B (zh) * | 2021-04-23 | 2023-11-07 | 渭南畅通药化科技有限公司 | 一种高纯度无气味的氯苯甘醚合成方法 |
| CN113087122B (zh) * | 2021-05-17 | 2022-09-27 | 江西师范大学 | 一种过一硫酸盐去除水解尿液中对乙酰氨基酚的方法 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1138405A (en) * | 1966-12-28 | 1969-01-01 | Ici Ltd | Morpholine derivatives |
| US3959273A (en) * | 1966-12-28 | 1976-05-25 | Imperial Chemical Industries Limited | Morpholine derivatives |
| US3876769A (en) * | 1967-11-24 | 1975-04-08 | Ici Ltd | Morpholine derivatives in the treatment of depression |
| US4116665A (en) * | 1976-04-02 | 1978-09-26 | Eli Lilly And Company | Method of regulating the growth of aquatic weeds with pyridine derivatives |
| IL56369A (en) * | 1978-01-20 | 1984-05-31 | Erba Farmitalia | Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them |
| GB8419683D0 (en) * | 1984-08-02 | 1984-09-05 | Erba Farmitalia | 3-substituted derivatives of 1-amino-2-hydroxy-propane |
| GB2167407B (en) * | 1984-11-22 | 1988-05-11 | Erba Farmitalia | Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof |
| US4855143A (en) * | 1986-04-04 | 1989-08-08 | Hans Lowey | Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics |
| US5750532A (en) * | 1986-12-10 | 1998-05-12 | Schering Corporation | Pharmaceutically active compounds |
| US5272167A (en) * | 1986-12-10 | 1993-12-21 | Schering Corporation | Pharmaceutically active compounds |
| US4851423A (en) * | 1986-12-10 | 1989-07-25 | Schering Corporation | Pharmaceutically active compounds |
| FR2612926B1 (fr) * | 1987-03-24 | 1989-06-09 | Adir | Nouveaux derives de la morpholine, leur procede de preparation et les compositions pharmaceutiques les renfermant |
| JPS641973A (en) * | 1987-06-25 | 1989-01-06 | Mitsubishi Electric Corp | Changeover abnormality detector for on-load tap changer |
| AU642582B2 (en) * | 1991-02-25 | 1993-10-21 | Eli Lilly And Company | Treatment of lower urinary tract disorders |
| DE19541264A1 (de) * | 1995-11-06 | 1997-05-07 | Bayer Ag | Purin-6-on-derivate |
| US6423708B1 (en) * | 1996-09-30 | 2002-07-23 | Pfizer Inc | Aralkyl and aralkylidene heterocyclic lactams and imides |
| US6314446B1 (en) * | 1997-03-31 | 2001-11-06 | Stiles Inventions | Method and system for monitoring tasks in a computer system |
| AU764184B2 (en) * | 1998-01-23 | 2003-08-14 | Pharmacia & Upjohn Company | Oxazolidinone combinatorial libraries, compositions and methods of preparation |
| US6562844B2 (en) * | 1998-01-23 | 2003-05-13 | Pharmacia & Upjohn Company | Oxazolidinone combinatorial libraries, compositions and methods of preparation |
| US5945117A (en) * | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
| US6528529B1 (en) * | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
| WO2000009491A1 (en) * | 1998-08-12 | 2000-02-24 | Smithkline Beecham Corporation | Calcilytic compounds |
| KR100616386B1 (ko) * | 1998-12-29 | 2006-08-28 | 파마시아 앤드 업존 캄파니 엘엘씨 | 아릴 에테르의 제조 방법 |
| ATE292971T1 (de) * | 1999-07-01 | 2005-04-15 | Upjohn Co | (s,s)-reboxetin zur behandlung von peripheren neuropathien |
| ATE358670T1 (de) * | 1999-09-16 | 2007-04-15 | Tanabe Seiyaku Co | Aromatische stickstoffhältige sechs-ring- verbindungen |
| US7273868B2 (en) * | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
| US6662318B1 (en) * | 2000-08-10 | 2003-12-09 | International Business Machines Corporation | Timely error data acquistion |
| EP1333835A1 (en) * | 2000-10-31 | 2003-08-13 | Head Explorer A/S | The use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache |
| US6789182B1 (en) * | 2000-11-13 | 2004-09-07 | Kevin Jay Brothers | System and method for logging computer event data and physical components of a complex distributed system |
| WO2002053104A2 (en) * | 2001-01-02 | 2002-07-11 | Sention, Inc. | Use of catecholamine reuptake inhibitors to enhance memory |
| US20040038860A1 (en) * | 2002-05-17 | 2004-02-26 | Allen Kristina M. | Reagents and methods for modulating dkk-mediated interactions |
| US20030019116A1 (en) * | 2001-07-30 | 2003-01-30 | Dewall Harlen E. | Drywaller tape measure |
| US6602911B2 (en) * | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
| US20040034101A1 (en) * | 2001-11-05 | 2004-02-19 | Cypress Bioscience, Inc. | Treatment and prevention of depression secondary to pain (DSP) |
| US6635675B2 (en) * | 2001-11-05 | 2003-10-21 | Cypress Bioscience, Inc. | Method of treating chronic fatigue syndrome |
| US20030187026A1 (en) * | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| US20050009927A1 (en) * | 2002-01-23 | 2005-01-13 | Pfizer Inc | Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors |
| US6962932B2 (en) * | 2002-02-15 | 2005-11-08 | Schering Aktiengesellschaft | 1-phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives |
| ES2399880T3 (es) * | 2002-03-15 | 2013-04-04 | Cypress Bioscience, Inc. | Milnaciprán para el tratamiento del síndrome del intestino irritable |
| US20040034019A1 (en) * | 2002-08-08 | 2004-02-19 | Ronald Tomlinson | Piperazine and piperidine derivatives |
| DE60324685D1 (de) * | 2002-08-23 | 2008-12-24 | Lilly Co Eli | 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin-wiederaufnahme-inhibitoren |
| ATE327982T1 (de) * | 2002-08-23 | 2006-06-15 | Lilly Co Eli | Benzylmorpholinderivate |
| AR043633A1 (es) * | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
| BRPI0414347A (pt) * | 2003-09-12 | 2006-11-07 | Warner Lambert Co | associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade |
| WO2005105763A1 (en) * | 2004-04-30 | 2005-11-10 | Warner-Lambert Company Llc | Substituted morpholine compounds for the treatment of central nervous system disorders |
| GB0409744D0 (en) * | 2004-04-30 | 2004-06-09 | Pfizer Ltd | Novel compounds |
| JP2010009449A (ja) * | 2008-06-30 | 2010-01-14 | Nec Corp | 分散情報配置システム |
-
2004
- 2004-04-30 GB GBGB0409744.0A patent/GB0409744D0/en not_active Ceased
-
2005
- 2005-04-15 DO DO2005000064A patent/DOP2005000064A/es unknown
- 2005-04-20 CN CNA2005800137802A patent/CN1950089A/zh active Pending
- 2005-04-20 MX MXPA06012640A patent/MXPA06012640A/es unknown
- 2005-04-20 CA CA2564990A patent/CA2564990C/en not_active Expired - Fee Related
- 2005-04-20 BR BRPI0510515-3A patent/BRPI0510515A/pt not_active IP Right Cessation
- 2005-04-20 AP AP2006003767A patent/AP2006003767A0/xx unknown
- 2005-04-20 KR KR1020087032112A patent/KR20090006888A/ko not_active Abandoned
- 2005-04-20 GE GEAP20059681A patent/GEP20084549B/en unknown
- 2005-04-20 UA UAA200611439A patent/UA86970C2/ru unknown
- 2005-04-20 EP EP05733458A patent/EP1744754A1/en not_active Withdrawn
- 2005-04-20 JP JP2007510152A patent/JP4181622B2/ja not_active Expired - Fee Related
- 2005-04-20 KR KR1020087032109A patent/KR20090006887A/ko not_active Abandoned
- 2005-04-20 NZ NZ550054A patent/NZ550054A/en unknown
- 2005-04-20 AU AU2005237301A patent/AU2005237301A1/en not_active Abandoned
- 2005-04-20 KR KR1020087032113A patent/KR20090006889A/ko not_active Ceased
- 2005-04-20 WO PCT/IB2005/001154 patent/WO2005105100A1/en active Application Filing
- 2005-04-20 EA EA200601802A patent/EA200601802A1/ru unknown
- 2005-04-20 KR KR1020077029225A patent/KR100896838B1/ko not_active Expired - Fee Related
- 2005-04-27 UY UY28873A patent/UY28873A1/es not_active Application Discontinuation
- 2005-04-28 GT GT200500098A patent/GT200500098A/es unknown
- 2005-04-28 PE PE2005000484A patent/PE20060305A1/es not_active Application Discontinuation
- 2005-04-28 US US11/117,896 patent/US20050250775A1/en not_active Abandoned
- 2005-04-28 AR ARP050101666A patent/AR048934A1/es not_active Application Discontinuation
- 2005-04-29 TW TW097146633A patent/TW200914431A/zh unknown
- 2005-04-29 SV SV2005002099A patent/SV2005002099A/es not_active Application Discontinuation
- 2005-04-29 TW TW094113999A patent/TWI309165B/zh not_active IP Right Cessation
- 2005-04-29 PA PA20058631601A patent/PA8631601A1/es unknown
- 2005-04-29 NL NL1028927A patent/NL1028927C2/nl not_active IP Right Cessation
-
2006
- 2006-09-21 NO NO20064282A patent/NO20064282L/no not_active Application Discontinuation
- 2006-09-26 IL IL178313A patent/IL178313A0/en unknown
- 2006-10-17 ZA ZA200608661A patent/ZA200608661B/en unknown
- 2006-10-27 EC EC2006006958A patent/ECSP066958A/es unknown
- 2006-10-27 NI NI200600257A patent/NI200600257A/es unknown
- 2006-10-27 CR CR8717A patent/CR8717A/es unknown
- 2006-10-27 TN TNP2006000347A patent/TNSN06347A1/fr unknown
- 2006-10-30 MA MA29417A patent/MA28554B1/fr unknown
-
2007
- 2007-11-21 JP JP2007301956A patent/JP2008106070A/ja active Pending
-
2008
- 2008-02-21 US US12/034,945 patent/US20080161309A1/en not_active Abandoned
-
2010
- 2010-02-09 US US12/702,383 patent/US20100137316A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20060305A1 (es) | Compuestos de morfolina como inhibidores de la recaptacion de monoaminas | |
| PE20050631A1 (es) | Compuestos derivados de amina como inhibidores de la reabsorcion de serotonina y de noradrenalina | |
| PE20050142A1 (es) | 2-hidroxi-3-diaminoalcanos de benzamida | |
| DOP2005000076A (es) | "compuestos de aril-o heteroarilamida ortosustituidos" | |
| PE20081475A1 (es) | Arilamidas sustituidas por tiazol u oxazol | |
| PE20081577A1 (es) | Derivados de sulfonamida ciclicos como inhibidores de la recaptacion de monoamina | |
| DOP2005000071A (es) | "compuestos de metil-aril o heteroaril-amida sustituida" | |
| PE20020346A1 (es) | Derivados de fenoxibencilamina como ssri | |
| AR041299A1 (es) | Derivados de pirrolidona como inhibidores de maob | |
| RS53348B (en) | PROCEDURE FOR THE PREPARATION OF 3-SUBSTITUTED 2-AMINO-5-HALOBENZAMIDES | |
| BRPI0413533A (pt) | derivados de malonamida que bloqueiam a atividade de gama-secretase | |
| PE20110152A1 (es) | Nuevos derivados de sulfamida sustituida | |
| PE20091473A1 (es) | Heterociclos como inhibidores de esteaoril-coa desaturasa | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| RU2012123154A (ru) | Способы лечения синдрома фибромиалгии | |
| PE20081782A1 (es) | Agonistas de adrenoreceptores alfa2c | |
| WO2004031160A3 (fr) | Composes derives de la 2-thiohydantoïne et leur utilisation pour le traitement du diabete | |
| PE20071251A1 (es) | Derivados de benzo-heteroaril sulfamida para el tratamiento del dolor | |
| AR069749A1 (es) | Proceso de dehidrohalogenacion para la preparacion de intermediarios utiles en el suministro de compuestos 6,6- dimetil-3-azabiciclo -(3.1.0)- hexano | |
| SE0401969D0 (sv) | Piperidine derivatives | |
| AR042362A1 (es) | Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen | |
| PE20120217A1 (es) | Derivados de carbamatos de alquil-heterociclos, su preparacion y su aplicacion en terapeutica | |
| PE20021018A1 (es) | DERIVADOS DE ß - CARBOLINA | |
| PE20001234A1 (es) | Compuestos azabiciclicos sustituidos de heteroaril-aminoetil/benzisoxazol como antagonistas serotonergicos 5-ht1 | |
| PE20120809A1 (es) | Antagonistas ccr3 arilsulfonamida 2,5-disustituidos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |